Outlook Therapeutics

Rank#9435

Market Cap144.36M

CountryUnited States

Summary

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

History

Outlook was founded in late 2013 to focus on the development of innovative pharmaceuticals. The company has developed its portfolio of novel compounds targeting various indications and is actively engaging in collaborations with research partners, venture capitalists, and universities.

Mission

Our mission is to develop innovative treatments for chronic diseases that can improve patients’ lives.

Vision

Outlook strives to be a leader in the development of novel treatments to address unmet medical needs.

References

https://in.investing.com/equities/oncobiologics-inc

https://finance.yahoo.com/quote/OTLK/profile?p=OTLK

https://www.crunchbase.com/organization/oncobiologics

https://companiesmarketcap.com/

https://www.outlooktherapeutics.com

Leadership team

Mr. Ralph H. Thurman (Independent Exec. Chairman)